Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial.

Aims: Imeglimin is a new oral anti-diabetic drug with a similar structure to that of metformin; however, unlike metformin, clinical trials indicate that imeglimin elicits its glucose-lowering effect mainly by enhancement of insulin secretion. The comparative effects of the two drugs on incretin secretion remains to be elucidated.

Materials And Methods: A single-center, open-label, randomized controlled trial was conducted in patients with type 2 diabetes who were drug-naïve or were on a single oral hypoglycaemic agent (OHA).

Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients.

Background: Efgartigimod was approved in Japan in January 2022 for the treatment of generalized myasthenia gravis (gMG), regardless of antibody status. This case series describes a real-world experience in Japan of efgartigimod treatment for gMG patients with diverse backgrounds.

Methods: We retrospectively analyzed the medical records of 16 Japanese patients (11 females and five males, mean age 40.

Experimental Formation and Mechanism Study for Super-High Dielectric Constant AlO/TiO Nanolaminates.

Super-high dielectric constant () AlO/TiO nanolaminates (ATO NLs) are deposited by an atomic layer deposition technique for application in next-generation electronics. Individual multilayers with uniform thicknesses are formed for the ATO NLs. With an increase in AlO content in each ATO sublayer, the shape of the Raman spectrum has a tendency to approach that of a single AlO layer.